Tamtam Try Tamtam free
Curaleaf logo

Curaleaf account plan

Leading cannabis product provider

At a glance

Curaleaf is a vertically integrated cannabis operator in 15 U.S. states and Europe: $1,268.1 million FY2025 revenue, 5,554 employees.

Curaleaf Holdings is a vertically integrated cannabis company that cultivates, extracts, manufactures and sells flower, pre-rolls, vapes, edibles and other products to consumers and patients in the U.S., Canada, Europe and Australasia. In the U.S. it sells through 188 owned and managed stores in 15 states (at September 30, 2026) and over 1,300 wholesale partner accounts; internationally it mostly wholesales medical cannabis, led by Germany, the U.K. and Poland. FY2025 total revenues, net were $1,268.1 million (down 5%), Adjusted EBITDA $274.7 million (22% margin) and the net loss attributable to Curaleaf $231.1 million; it had 5,554 employees at December 31, 2025. Incorporated in British Columbia and headquartered in Stamford, Connecticut, its subordinate voting shares are listed on the TSX as CURA and quoted on the OTCQX as CURLF, with a U.S. redomicile planned.

Business units

Strategic priorities

U.S. retail and brand share
Strengthen the U.S. retail platform through store-level execution, product availability and customer experience, with priority states Florida, Illinois, New Jersey and Pennsylvania. The company expects to end 2026 with around 89-90 Florida stores, up from about 65, and intends to play in Georgia and Texas.
International expansion
Grow patient adoption in Germany, the U.K. and Poland and open new markets: Spain sales start in November 2026, a French pharma distribution partnership targets a 2027 launch, and Turkey, where Curaleaf holds the only foreign-issued license, is expected to start in 2027.
International supply self-sufficiency
About 20% of international supply comes from its own facilities; the target is 50% to 75% within 6 to 12 months through Portugal and Canada expansion, acquisitions and later U.S. exports, cutting cash conversion from about 120 days to less than 60 days.
Cost and operating efficiency
A plan to cut $20 million of expenses in H2 2026 and a program to take $35 to $40 million out of SG&A over 12 months, alongside supply chain modernization and investment in data analytics, merchandising and assortment optimization.
Federal reform and capital markets
Medical cannabis moved to Schedule III in April 2026, so medical activity on or after April 28, 2026 is no longer limited by Section 280E; the company is prepared to uplist the entire company to a major U.S. exchange once adult-use is rescheduled, and plans a U.S. redomicile.

Latest results

In Q3 2026 (quarter to September 30, 2026) total revenues, net rose 11% to $352.7 million, with retail up 8% to $242.6 million and wholesale up 21% to $106.2 million; domestic grew 8% and international 28%. Gross margin fell to 48% from 51% and operating expenses rose 9% to $167.5 million, but Adjusted EBITDA increased to $77.6 million (22% margin) from $71.7 million, and the net loss from continuing operations narrowed to $37.4 million. Over nine months, revenue was $1,017.0 million (up 9%) and net income attributable to Curaleaf $49.6 million, helped by a $121.2 million release of uncertain tax positions. Management guides Q4 revenue up 1% to 2% sequentially (about $358 million at the midpoint), gross margin of 48-49%, roughly flat EBITDA, about $150 million of 2026 operating cash flow and about $80 million of capex.

Investments and deals

Aurora Cannabis takeover bid
Offer launched in August 2026 and raised on October 6, 2026 to $1.00 cash plus 0.4013 SVS per Aurora share, open until December 4, 2026. Aurora's board recommended a competing Organigram arrangement on November 3, 2026; Curaleaf says it would improve its bid only with due diligence access.
Four20 Pharma buyout
The sellers of Four20 Pharma GmbH in Germany exercised their put on the remaining 45% on February 23, 2026 (expected price $80.0 million to $100.0 million, cash and stock); Curaleaf bought the 45% in April 2026.
Refinancing
$500.0 million of 11.5% senior secured notes due 2029 placed on February 18, 2026 to repay the 2026 notes; the Needham revolving line was raised from $40 million to $100 million in October 2025. Notes payable were $636.9 million at September 30, 2026.
Store and capacity growth
Eight new dispensaries opened in 2025 across Florida, Maine and Ohio; a facility bought in Ohio more than doubled capacity there. Capex was $63.4 million in FY2025 and is expected at about $80 million for 2026.
Portfolio exits
Hemp-derived THC and Missouri were exited and reclassified as discontinued operations on December 30, 2025; cannabis beverages will be pursued only within regulated cannabis frameworks.

Challenges and risks

U.S. price compression and competition
Retail competition, new market entrants and market saturation lowered transaction volumes and prices; domestic FY2025 revenue fell 11%, and wholesale price compression hit New York, New Jersey and Illinois in Q3 2026.
German price collapse
German prices fell from about $3 a gram to $0.90 a gram in one quarter as some Canadian producers dumped product, and October 2026 was described as the worst month since the market began.
Federal illegality and Section 280E
Adult-use cannabis remains under Section 280E, and Schedule I status limits banking, financing and bankruptcy access; the company holds reserves for an uncertain tax position on 280E.
Leverage and dilution
Notes payable of $636.9 million against cash of $104.9 million at September 30, 2026; the Aurora offer, if completed, requires cash and dilutes existing shareholders.
European regulatory risk
Licensing, reimbursement, prescriber adoption, reliance on third-party distributors and protectionist policies are named risks for the international business.

What leadership says

“we have moved from stabilization to acceleration”

Boris Jordan, Chairman and Chief Executive Officer · Curaleaf Q2 2026 earnings call, August 5, 2026

“So today we provide about 20% of our supply comes from our own facilities. We'd like to increase that to somewhere between 50% and 75%.”

Boris Jordan, Chairman and Chief Executive Officer · Curaleaf Q2 2026 earnings call, August 5, 2026

“It's not the EU GMP certification that's the most important thing. It's the supply chain that's the most important thing and at the right price.”

Boris Jordan, Chairman and Chief Executive Officer · Curaleaf Q3 2026 earnings call, November 3, 2026

“We intend to end the year at around 89, 90 stores in Florida”

Boris Jordan, Chairman and Chief Executive Officer · Curaleaf Q3 2026 earnings call, November 3, 2026

Where a supplier can help

EU-GMP contract supply and logistics
Tied to the international supply priority: with only about 20% of supply from its own facilities and a 50% to 75% target, EU-GMP cultivators, contract manufacturers and pharma logistics providers can help raise margins and shorten cash conversion.
Retail analytics and merchandising tools
Tied to U.S. price compression and the 2026 push into data analytics, merchandising and assortment optimization: pricing, loyalty and store-execution software can support share gains in priority states.
Florida store build-out
Tied to the plan to reach around 89-90 Florida stores by end of 2026: fit-out, security, fixtures and point-of-sale suppliers serve a fast-growing store base.
Cost-reduction programs
Tied to the $35 to $40 million SG&A program and the company's AI committee deploying tools in pricing, merchandising, IT, legal, finance and operations: automation and outsourcing vendors can show measurable savings.
Market-entry services in new countries
Tied to international expansion into Spain, France and Turkey: regulatory, pharmacy distribution and patient-education partners can speed launches.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Curaleaf?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Curaleaf

What does Curaleaf do?

Curaleaf is a vertically integrated cannabis company that grows, processes and sells cannabis products through its own U.S. dispensaries and wholesale accounts, and supplies medical cannabis in Europe and Australasia.

What is Curaleaf's revenue?

FY2025 total revenues, net were $1,268.1 million, down 5% from $1,334.3 million. Q3 2026 revenue was $352.7 million, up 11%.

How many employees does Curaleaf have?

Curaleaf had 5,554 employees at December 31, 2025: 4,862 in the U.S., 92 in Canada, 598 in Europe and 2 in Australia.

Who leads Curaleaf?

Boris Jordan is Chairman and CEO, Rahul Pinto is President, Ed Kremer is CFO and Joseph Lusardi is Executive Vice Chairman.

What is Curaleaf's strategy?

It pursues U.S. market leadership in limited-license states, international expansion in medical markets such as Germany, the U.K., Poland, Spain, France and Turkey, and science-led R&D, under its Built for Growth framework.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)